John M. Kaczmar
Expertise in
22
conditions

Dr. John M. Kaczmar

Hematology | Oncology
Musc Hollings Cancer Center
86 Jonathan Lucas St, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Musc Hollings Cancer Center
86 Jonathan Lucas St, 
Charleston, SC 

Overview

Dr. John Kaczmar is a medical oncologist who specializes in caring for patients with cancers of the head and neck. He attended college at Cornell University, graduating Phi Beta Kappa. He then obtained his medical degree at Columbia University Medical School in New York City, where he served as president of his class. After medical school, he undertook a residency in internal medicine at the Hospital of the University of Pennsylvania. There, he served as a member of the resident steering committee and attained an additional certification in health care leadership in quality. Following this, he completed a fellowship in hematology and oncology at the Fox Chase Cancer Center in Philadelphia, before joining the Medical University of South Carolina in 2017.There are many challenges involved in treating cancers of the head and neck. Dr. Kaczmar's research interests are focused on overcoming these challenges through the use of the body's own immune system (immunotherapy) and targeted therapies aimed at fighting head and neck cancer growth. In addition to bringing cutting-edge treatment options to patients, he has an interest in working to improve the tolerability of proven treatments so as to maximize quality of life.

Dr. Kaczmar is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Glioma, and Thyroid Cancer.

He is actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 11 clinical trials. Dr. Kaczmar is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in PA

Hospital Affiliations

Musc Medical Center
Trident Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Musc Hollings Cancer Center
86 Jonathan Lucas St, Charleston, SC 29425

Additional Areas of Focus

Dr. Kaczmar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 23, 2026
Intervention Type: Radiation, Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: January 28, 2026
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA®) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Combination product
Study Drugs: Pembrolizumab, PDS0101
Study Phase: Phase 2
Pilot Clinical Trial of Neoadjuvant Toll-like Receptor 7 Agonist (Imiquimod) Immunotherapy in Early-Stage Oral Squamous Cell Carcinoma
Pilot Clinical Trial of Neoadjuvant Toll-like Receptor 7 Agonist (Imiquimod) Immunotherapy in Early-Stage Oral Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug
Study Drug: Imiquimod
Study Phase: Early Phase 1
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug, Biological
Study Drugs: Ficlatuzumab, Cetuximab
Study Phase: Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 9 Less Clinical Trials

41 Total Publications

Mechanisms Underlying an Enhanced Navigation-Based Intervention to Improve Timely Adjuvant Therapy: A Secondary Analysis of the NDURE Randomized Clinical Trial.
Mechanisms Underlying an Enhanced Navigation-Based Intervention to Improve Timely Adjuvant Therapy: A Secondary Analysis of the NDURE Randomized Clinical Trial.
Journal: JAMA otolaryngology-- head & neck surgery
Published: July 23, 2026
Similar Doctors
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (0.2 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
29
conditions
Dr. Gene B. Saylors
Hematology | Oncology
Expertise in
29
conditions
Dr. Gene B. Saylors
Hematology | Oncology
Referral may be required

Bon Secours St Francis Xavier Hospital Inc.

2910 Tricom St, 
North Charleston, SC 
 (15.0 miles away)
843-572-9211
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gene Saylors is a Hematologist and an Oncologist practicing medicine in North Charleston, South Carolina. Dr. Saylors is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Pancreatectomy. Dr. Saylors is currently accepting new patients.

Expertise in
28
conditions
Dr. Irl Greenwell
Hematology | Oncology
Expertise in
28
conditions
Dr. Irl Greenwell
Hematology | Oncology
Referral may be required

Charleston Oncology West Ashley

2085 Henry Tecklenburg Dr, 
Charleston, SC 
 (5.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Irl Greenwell is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Greenwell is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Greenwell is currently accepting new patients.

Frequently Asked Questions about Dr. John M. Kaczmar

Is Dr. John M. Kaczmar a top-rated expert for Head and Neck Squamous Cell Carcinoma (HNSCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John M. Kaczmar is classified as an Distinguished expert for Head and Neck Squamous Cell Carcinoma (HNSCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John M. Kaczmar specialize in?

While Dr. John M. Kaczmar is a Hematology, they have specific expertise in Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. John M. Kaczmar participate in research or clinical trials?

Yes. Dr. John M. Kaczmar has published 41 articles and abstracts on conditions like Head and Neck Squamous Cell Carcinoma (HNSCC). You can view a list of Dr. John M. Kaczmar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John M. Kaczmar accept my insurance?

Dr. John M. Kaczmar accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kaczmar's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile